Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01069575 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 18 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01069640 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01949701 |
| Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer |
| completed |
| Phase 1 / Phase 2 |
| 6 |
| Shiga UniversityOTHER |
| 1 |
| Mar 19, 2019 |
| clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00153842 | A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 33 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02846792 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | University of WashingtonOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC(PRIMAL) | terminated | Phase 1 | 16 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01999738 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | completed | Phase 1 | 93 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT02258607 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | terminated | Phase 1 | 21 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03053219 | Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02364362 | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT03556436 | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 | completed | Phase 1 | 24 | Yuhan CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | PfizerINDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT01323062 | Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | completed | Phase 1 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT02457793 | A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00745732 | Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00735878 | Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 20 | Konstantin DragnevOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02580708 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Clovis Oncology, Inc.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00352950 | Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 6, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT01457469 | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer | completed | Phase 1 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02835833 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | completed | Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT00923741 | Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery | terminated | Phase 1 | 60 | GlaxoSmithKlineINDUSTRY | 6 | Jun 18, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT02252796 | Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer(HySBst) | terminated | Phase 1 | 1 | West Virginia UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01607554 | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 2 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Mar 19, 2019source: clinicaltrials